These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8281242)

  • 1. Clinical pharmacological issues in treating psychiatric disorders of patients with mental retardation.
    Arnold LE
    Ann Clin Psychiatry; 1993 Sep; 5(3):189-97. PubMed ID: 8281242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating behavioral and pharmacological interventions in treating clients with psychiatric disorders and mental retardation.
    Sevin JA; Bowers-Stephens C; Hamilton ML; Ford A
    Res Dev Disabil; 2001; 22(6):463-85. PubMed ID: 11768671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The international consensus process on psychopharmacology and intellectual disability.
    Reiss S; Aman MG
    J Intellect Disabil Res; 1997 Dec; 41 ( Pt 6)():448-55. PubMed ID: 9430048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychopharmacotherapy in children and adults with intellectual disability.
    Santosh PJ; Baird G
    Lancet; 1999 Jul; 354(9174):233-42. PubMed ID: 10421318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychotropic medication use in children and adolescents in an inpatient setting.
    Pejovic-Milovancevic M; Miletic V; Popovic-Deusic S; Draganic-Gajic S; Lecic-Tosevski D; Marotic V
    Psychiatriki; 2011; 22(4):314-9. PubMed ID: 22271844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior.
    Tsiouris JA; Cohen IL; Patti PJ; Korosh WM
    J Clin Psychiatry; 2003 Sep; 64(9):1081-90. PubMed ID: 14628984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of problem behaviour during medication evaluations.
    Zarcone J; Napolitano D; Valdovinos M
    J Intellect Disabil Res; 2008 Dec; 52(12):1015-28. PubMed ID: 18717764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic management of psychiatric and behavioral symptoms in mental retardation.
    Madrid AL; State MW; King BH
    Child Adolesc Psychiatr Clin N Am; 2000 Jan; 9(1):225-43, x-xi. PubMed ID: 10674198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of psychotropic medications for persons with mental retardation who live in Oklahoma nursing homes.
    Spreat S; Conroy J
    Psychiatr Serv; 1998 Apr; 49(4):510-2. PubMed ID: 9550242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Professionals' perceptions of psychotropic medication in residential facilities for individuals with mental retardation.
    Singh NN; Ellis CR; Donatelli LS; Williams DE; Ricketts RW; Goza AB; Perlman N; Everly DE; Best AM; Singh YN
    J Intellect Disabil Res; 1996 Feb; 40 ( Pt 1)():1-7. PubMed ID: 8930051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practitioner versus medication-expert opinion on psychiatric pharmacotherapy of mentally retarded patients with mental disorders.
    Patel NC; Crismon ML; Rush AJ; Frances A
    Am J Health Syst Pharm; 2001 Oct; 58(19):1824-9. PubMed ID: 11596698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the utility of atypical antipsychotic medication in adults with mild mental retardation and comorbid psychiatric disorders.
    Shedlack KJ; Hennen J; Magee C; Cheron DM
    J Clin Psychiatry; 2005 Jan; 66(1):52-62. PubMed ID: 15669889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Mini Mental State in those with developmental disabilities.
    Myers BA
    J Nerv Ment Dis; 1987 Feb; 175(2):85-9. PubMed ID: 2433389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Informed consent for medication in persons with mental retardation and mental illness.
    O'Sullivan JL; Borcherding BG
    Health Matrix Clevel; 2002; 12(1):63-92. PubMed ID: 12013701
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnosis and treatment considerations with comorbid developmentally disabled populations.
    Fuller CG; Sabatino DA
    J Clin Psychol; 1998 Jan; 54(1):1-10. PubMed ID: 9476703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A guide to psychopharmacological treatment of patients with intellectual disability in psychiatry.
    Molina-Ruiz RM; Martín-Carballeda J; Asensio-Moreno I; Montañés-Rada F
    Int J Psychiatry Med; 2017 Mar; 52(2):176-189. PubMed ID: 28792289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychopathology in people with epilepsy and intellectual disability; an investigation of potential explanatory variables.
    Espie CA; Watkins J; Curtice L; Espie A; Duncan R; Ryan JA; Brodie MJ; Mantala K; Sterrick M
    J Neurol Neurosurg Psychiatry; 2003 Nov; 74(11):1485-92. PubMed ID: 14617702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypharmacy and the lack of oculo-visual complaints from those with mental illness and dual diagnosis.
    Donati RJ; Maino DM; Bartell H; Kieffer M
    Optometry; 2009 May; 80(5):249-54. PubMed ID: 19410230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychiatric and behavioural disorders amongst older severely mentally handicapped inpatients.
    James DH
    J Ment Defic Res; 1986 Dec; 30 ( Pt 4)():341-5. PubMed ID: 3806661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Problem behavior and psychiatric impairment within a developmentally disabled population. III: Psychotropic medication.
    Jacobson JW
    Res Dev Disabil; 1988; 9(1):23-38. PubMed ID: 3353539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.